ASX Announcements

Quarterly Cashflow Report - Period ending 31 March 2026

Apr 28, 2026

FDA Confirms Single Pivotal Trial Pathway for Elate Ocular

Apr 23, 2026

Quarterly Cashflow Report - Period ending 31 December 2025

Jan 30, 2026

Cambium Bio Secures A$2.4 Million Strategic Investment from Major Shareholder ZYBT

Jan 20, 2026

Quarterly Cashflow Report - Period Ending 30 September 2025

Oct 31, 2025

Quarterly Cashflow Report - Period ending 30 June 2025

Jul 31, 2025

Cambium Bio Raises $2.12M via Fully-Subscribed Placement

Jul 30, 2025

Cambium Bio Clears FDA Regulatory Hurdles to Commence Phase 3 Dosing for Elate Ocular

Jul 11, 2025

Cambium Bio Receives Ethics Approvals

Jun 30, 2025

Quarterly Cashflow Report & Business Update-March 2024

Apr 28, 2025

Change of registry address notification

Apr 14, 2025

Notice of ceasing to be a substantial holder-CMB

Apr 11, 2025

Cambium Bio - Release of Shares from Escrow

Mar 21, 2025

Notice of change of interests of substantial holder-CMB 18 Mar 2025

Mar 18, 2025

FDA Approves Cambium Bio's Potency Assay Strategy for Elate Ocular Phase 3 Clincial Trials

Mar 18, 2025

Change of Directors Interest Notice - 12 Mar 25

Mar 12, 2025

Notification regarding unquoted securities - 12 Mar 25

Mar 12, 2025

Application for quotation of securities - 12 Mar 25

Mar 12, 2025

Mr Chiu - Director Appointment and Appedix 3X

Mar 7, 2025

2025.03.04 Results of General Meeting

Mar 4, 2025

2025.03.03 Response to queries re Appendices 3X and 3Z

Mar 3, 2025

Update-Proposed issue of securities - CMB 28 Feb 2025

Feb 28, 2025

Half-Year Report FY2025

Feb 27, 2025

FDA Approves Elate Ocular® Phase 3 Clinical Trial Protocol

Feb 25, 2025

Application for quotation of securities - 13 Feb 2025

Feb 13, 2025

Placement Shares Cleansing Notice - 13 Feb 2025

Feb 13, 2025

Quarterly Cashflow Report & Business Update-December 2024

Jan 31, 2025

Notice and General Meeting and Proxy-4 March 2025

Jan 30, 2025

Application for quotation of securities - 12 Dec 2024

Dec 12, 2024

Placement Shares Cleansing Notice 12 Dec 2024

Dec 12, 2024

FDA Grants Fast Track Designation

Dec 9, 2024

Proposed issue of securities - CMB

Dec 5, 2024

Cambium Bio Successfully Closes A$3.0M Financing Round

Dec 5, 2024

AGM results and Re-appointment of Dr Bala

Nov 26, 2024

Cambium CEO AGM Presentation

Nov 26, 2024

Appendix 3B - Proposed issue of securities

Nov 22, 2024

Cambium Bio Board Changes

Nov 22, 2024

Quarterly Cashflow Report & Business Update - September 2024

Oct 30, 2024

CEO Acquires Additional Shares Demonstrating Strong Confidence in the Company

Oct 15, 2024

Initial Director’s Interest Notice - Chang

Oct 10, 2024

Cambium Bio Strengthens Leadership with Two Key Appointments

Oct 10, 2024

Date of AGM 2024

Oct 2, 2024

CEO Revised Engagement Agreement Terms

Aug 30, 2024

Appendix 4G and Corporate Governance Statement

Aug 30, 2024

Cambium 4E and Annual Report

Aug 30, 2024

Quarterly Cashflow Report & Business Update - June 2024

Jul 31, 2024

Notice of change of interests of substantial holder-Treasure

Jul 31, 2024

Notice of change of interests of substantial holder-Apex

Jul 31, 2024

Notice of change of interests of substantial holder-CMB

Jul 19, 2024

Change of directors interest

Jul 12, 2024

Share Consolidation Completion

Jul 12, 2024

Appendix 3H - Notification of cessation of securities

Jul 9, 2024

Change in substantial holding-Cyntec

Jul 4, 2024

Change in substantial holding-Treasure

Jul 2, 2024

Change in substantial holding-Apex

Jul 2, 2024

Becoming a substantial holder-Treasure

Jul 2, 2024

Becoming a substantial holder-Apex

Jul 2, 2024

Appendix 3Y-Sebastian Tseng

Jul 1, 2024

Placement Shares Cleansing Notice-Tranche 2

Jun 28, 2024

Application for quotation of securities - CMB

Jun 28, 2024

Results of General Meeting

Jun 25, 2024

Correction to Notice of General Meeting

Jun 13, 2024

Appendix 3A.3 - Security Consolidation

May 23, 2024

Notice of Share Consolidation

May 23, 2024

Letter to Shareholder - General Meeting

May 23, 2024

Notice of Meeting & proxy

May 23, 2024

Becoming a substantial holder - Cyntec

May 14, 2024

Becoming a substantial holder - ZYBT

May 14, 2024

Response to ASX Aware Query

May 1, 2024

Quarterly Cashflow Report and Business Update - period ending 31 March 2024

Apr 30, 2024

Notice of change of interests of substantial holder

Apr 11, 2024

Director's Appointment - Dr. Tseng

Apr 11, 2024

Initial DIrector's Interest Notice - Dr. Tseng

Apr 11, 2024

Placement Shares Cleansing Notice

Apr 10, 2024

Application for quotation of securities (10 April 2024)

Apr 10, 2024

Proposed issue of securities

Apr 8, 2024

Change of company name and ASX code

Apr 8, 2024

Ceasing to be a substantial holder - Vesey

Apr 8, 2024

Ceasing to be a substantial holder - Lee

Apr 8, 2024

Ceasing to be a substantial holder - Kirman 2

Apr 8, 2024

Resignation of Non-Executive Director - Lee

Apr 5, 2024

Consideration Shares Cleansing Notice

Apr 5, 2024

Notice of initial substantial holder

Apr 5, 2024

Application for quotation of securities

Apr 5, 2024

Final Director's Interest Notice - Lee

Apr 5, 2024

Initial Director's Interest Notice - Walts

Apr 5, 2024

Initial Director's Interest Notice - Waller

Apr 5, 2024

Cambium Bio Raises A$3.48 Million in Strategic Placement

Apr 8, 2023

Regeneus Completes Merger with Cambium Medical Technologies LLC

Apr 8, 2023

Back to Investors and Media

For all Cambium Bio Limited ASX market announcements, click here